Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice.
Rania SalahMohamed F SalamaHebatallah A MahgoubEl-Said El-SherbiniPublished in: Journal of biochemical and molecular toxicology (2020)
This study was carried out to investigate the potential effects of vitamin B12 and sitagliptin, and their possible synergistic effect with doxorubicin (DOX) on the Ehrlich solid tumor model. B12, sitagliptin, and their combination with DOX were administered to tumor-bearing mice for 21 days. Treatment with B12, sitagliptin, as well as their combinations with DOX caused a significant inhibition of tumor growth and increased the survival time. Malondialdehyde levels and the relative expression of tumor necrosis factor-α and nuclear factor kappa B were significantly decreased, whereas the total antioxidant capacity was significantly increased in all treated groups, except the DOX-treated one, when compared with the positive control group. Moreover, increased apoptosis was also observed by increased cleaved caspase-3 immunostaining and histopathological examination. In conclusion, the antitumor activity of B12 and sitagliptin could be attributed to their ability to induce apoptosis and suppress oxidative stress and inflammation.
Keyphrases
- oxidative stress
- nuclear factor
- cell death
- toll like receptor
- endoplasmic reticulum stress
- induced apoptosis
- dna damage
- high fat diet induced
- poor prognosis
- cell cycle arrest
- ischemia reperfusion injury
- diabetic rats
- rheumatoid arthritis
- risk assessment
- immune response
- signaling pathway
- wild type
- cell proliferation
- long non coding rna
- climate change
- replacement therapy
- smoking cessation
- human health